GlassScriptPhysician profile
Pinal Patel
NPI 1427190891
$2,022.27
in general payments reported to CMS, 2019-2025
28 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $485 · 2023: $392 · 2024: $455 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $370.42 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $240.87 | 2021-2025 | |
| Abbott Laboratories | $193.93 | 2022-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $183.58 | 2021-2025 | Veozah |
| Lilly USA, LLC | $126.70 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $109.70 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $101.34 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $78.26 | 2024-2025 | Airsupra |
| Daiichi Sankyo INC. | $70.10 | 2023-2025 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $70.08 | 2022-2024 | Austedo Xr |
| Pfizer INC. | $62.58 | 2022-2025 | |
| Hologic Sales and Service, LLC | $58.40 | 2023 | Thinprep 2000 Processor, Affirm Prone Biopsy System, Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.41 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $45.63 | 2021-2022 | |
| Corcept Therapeutics | $43.30 | 2025 | Korlym |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $19.74 | 2024 | Inspire |
| Biogen, INC. | $18.79 | 2024 | Spinraza, Skyclarys |
| Amneal Pharmaceuticals LLC | $18.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.66 | 2024 | |
| Medtronic, INC. | $17.30 | 2024 | Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $17.08 | 2025 | |
| Idorsia Pharmaceuticals US INC | $17.00 | 2023 | Quviviq |
| Irhythm Technologies, INC. | $15.94 | 2022 | |
| Amgen INC. | $14.97 | 2023 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.97 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.58 | 2021 | |
| Almatica Pharma LLC | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pinal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.